The companies plan to launch a post-market U.S. pilot study in the third quarter of 2021 to gain insights on how physicians can use AliveCor’s KardiaMobile electrocardiogram (ECG) device to facilitate pre-ablation and/or post-ablation remote monitoring to aid in the decision making while managing cardiac arrhythmia patients, according to a news release.
Information gathered through the collaboration is intended to enable more informed decisions in treating complex arrhythmias to potentially improve patient outcomes and advance the field of arrhythmia treatment and disease management, the companies said.
“Utilizing data from across the continuum of care to complement our core mapping and therapy technologies furthers our vision to become the provider-of-choice and democratize the treatment of complex arrhythmia patients,” Acutus president & CEO Vince Burgess said in the release. “AliveCor will be an excellent partner to help our physicians assess important clinical patient information as they manage and treat their cardiac arrhythmia patients.”
Acutus’ offerings in the collaboration include a portfolio of highly differentiated electrophysiology tools and products for the catheter-based treatment of cardiac arrhythmias, including the AcQMap 3D imaging and mapping system.
“AliveCor is proud to partner with Acutus to advance understanding of the use of our shared technologies and how we can potentially improve the care and monitoring of cardiac patients,” added AliveCor CEO Priya Abani.